Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Sapienza

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Drug and Alcohol Dependence|March 15, 2006
Abuse deterrent formulations and the Controlled Substances Act (CSA)Frank L Sapienza
Physical Review Letters|June 4, 2008
Electrically injected cavity polaritonsL Sapienza, A Vasanelli, R Colombelli, et al.
Molecular Psychiatry|May 28, 2024
Letter to the Editor regarding 'Unique pharmacodynamic properties and low abuse liability of the µ-opioid receptor ligand (S)-methadone'Marco Pappagallo, Thomas R Kosten, Charles W Gorodetzky, et al.
The Journal of Clinical Psychiatry|February 25, 2025
Long-Term Safety and Efficacy of Esmethadone in Patients With Major Depressive Disorder: Findings From a 12-Month Open-Label StudyMaurizio Fava, Luca Pani, Sara De Martin, et al.
The Journal of Clinical Psychiatry|June 25, 2024
Efficacy and Safety of Esmethadone (REL-1017) in Patients With Major Depressive Disorder and Inadequate Response to Standard Antidepressants: A Phase 3 Randomized Controlled TrialMaurizio Fava, Stephen M Stahl, Luca Pani, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Drug and Alcohol Dependence|March 15, 2006
Abuse deterrent formulations and the Controlled Substances Act (CSA)Frank L Sapienza
Physical Review Letters|June 4, 2008
Electrically injected cavity polaritonsL Sapienza, A Vasanelli, R Colombelli, et al.
Molecular Psychiatry|May 28, 2024
Letter to the Editor regarding 'Unique pharmacodynamic properties and low abuse liability of the µ-opioid receptor ligand (S)-methadone'Marco Pappagallo, Thomas R Kosten, Charles W Gorodetzky, et al.
The Journal of Clinical Psychiatry|February 25, 2025
Long-Term Safety and Efficacy of Esmethadone in Patients With Major Depressive Disorder: Findings From a 12-Month Open-Label StudyMaurizio Fava, Luca Pani, Sara De Martin, et al.
The Journal of Clinical Psychiatry|June 25, 2024
Efficacy and Safety of Esmethadone (REL-1017) in Patients With Major Depressive Disorder and Inadequate Response to Standard Antidepressants: A Phase 3 Randomized Controlled TrialMaurizio Fava, Stephen M Stahl, Luca Pani, et al.
Pageof 1